This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Solid Organ Transplantation
  • /
  • Belatacept-based Immunosuppression: A Calcineurin ...
Journal

Belatacept-based Immunosuppression: A Calcineurin Inhibitor-Sparing Regimen in Heart Transplant Recipients

Read time: 1 mins
Published:31st Jan 2020
Author: Launay M, Guitard J, Dorent R, et al.
Ref.:Am J Transplant. 2020;20(2):553‐563.
DOI:10.1111/ajt.15584

Belatacept (BTC ) is indicated for prophylaxis of graft rejection in adults receiving a renal transplant (Tx). This retrospective observational study (three centers) included all heart transplant recipients receiving BTC between January 2014 and October 2018. Forty EBV + patients mean GFR 35 ± 20 mL /min/m2 were identified, among whom belatacept was initiated during the first 3 months after transplantation in 12 patients, and later in 28 patients. Several patients were multiorgan transplant recipients. Study outcomes were GFR , safety, and changes in immunosuppressive therapy. The main reason for switching to BTC was to preserve renal function, resulting in discontinuation of CNI and changes in immunosuppressive therapy in 76% of cases. At study closeout, 24/40 patients were still on BTC therapy. GFR was improved (+59%, P = .0002*) within 1 month, particularly in the early group. More episodes of rejection were observed among “late” patients (1 death). Sixteen treatment discontinuations were recorded: GFR recovery (n = 4), DSA no longer detectable (n = 1), compliance issues (n = 3), poor venous access (n = 2), multiple infections (n = 1), 1 death (fungal lung infection), and treatment failure (n = 4). Median follow‐up was 24 months. Four patients developed de novo DSA (MFI <1500). BTC is an effective alternative immunosuppressive for postoperative transient kidney failure, stabilizing delayed renal function, with acceptable safety profile under careful monitoring.


Read abstract on library site Access full article